Web展会信息. 【行业资讯】新药资讯 超80%患者肿瘤显著缩小或稳定!. 肺癌国研新药 谷美替尼震撼上市. 谷美替尼(SCC244)是一种国研高选择性 MET 抑制剂,够选择性抑制c-Met激酶活性,进而抑制肿瘤细胞的增殖、迁移和侵袭。. 在携带 MET 外显子 14 跳跃突变的非小 ... WebJXHL1400299 INC280片 化药 进口 2014-09-18 JXHL1400304 Ledipasvir/Sofosbuvir Tablet 化药 进口 2014-09-18 ... CXHL1401166 达格列净片 北京阳光诺和药物研究有限公司,吉林四环制药有限公司,吉林德通医药科技有限公司 化药 新药 3.1 2014-09-18 CXHL1401165 达格列净片 北京阳光诺和药物研究 ...
Capmatinib (INC280) Is Active Against Models of Non–Small Cell …
WebMay 25, 2024 · 9509 Background: In the ongoing, multicohort, phase 2 GEOMETRY mono-1 study, capmatinib (INC280) has shown efficacy in METex14–mutated NSCLC patients (pts) who were pretreated (cohort 4) or treatment (tx)-naïve (cohort 5b). Here, we report the efficacy and safety of capmatinib in pts with high-level MET-amplified (gene copy number … WebMay 15, 2024 · Capmatinib (INC280, formerly INCB28060) is a highly selective and potent MET inhibitor with in vitro and in vivo activities against preclinical cancer models with … how to stream fantasy island
Capmatinib(INC280、卡马替尼)_肺癌_抗癌药物_全球肿瘤医生网
WebBackground. Among patients with non–small-cell lung cancer (NSCLC), MET exon 14 skipping mutations occur in 3 to 4% and MET amplifications occur in 1 to 6%. Capmatinib, a selective inhibitor of ... WebMar 1, 2024 · INC280, a MET-selective tyrosine kinase inhibitor, and trametinib, a mitogen-activated protein kinase kinase (MEK) inhibitor, were obtained from the Neal Rosen research group at Memorial Sloan Kettering. PDX-bearing mice were treated with cetuximab or with INC280 and trametinib following previously reported methods . Briefly, cetuximab was ... WebMar 12, 2015 · INC280 is a highly potent and selective c-MET inhibitor which also penetrates the blood-brain barrier. In this open-label, multicenter Phase 1b study, investigators determined the optimal dose of the INC280/bevacizumab combination to administer to patients. Enrollment has now expanded in order to treat 3 cohorts of GBM patients: those … reading 1oeso